These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23202863)

  • 1. [Treatment results of nasopharyngeal carcinoma in adults].
    Jakob M; Manz M; Herberhold S; Schröck A; Gerstner AO; Schüller H; Eichhorn KW
    HNO; 2012 Dec; 60(12):1075-81. PubMed ID: 23202863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns.
    Leung TW; Tung SY; Sze WK; Wong FC; Yuen KK; Lui CM; Lo SH; Ng TY; O SK
    Head Neck; 2005 Jul; 27(7):555-65. PubMed ID: 15880410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasopharyngeal carcinoma in a low incidence European area : A prospective observational analysis from the Head and Neck Study Group of the Italian Society of Radiation Oncology (AIRO).
    Tonoli S; Alterio D; Caspiani O; Bacigalupo A; Bunkheila F; Cianciulli M; Merlotti A; Podhradska A; Rampino M; Cante D; Bruschieri L; Gatta R; Magrini SM
    Strahlenther Onkol; 2016 Dec; 192(12):931-943. PubMed ID: 27761611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.
    Li XY; Chen QY; Sun XS; Liu SL; Yan JJ; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Wen YF; Guo L; Mo HY; Chen MY; Sun Y; Ma J; Tang LQ; Mai HQ
    Eur J Cancer; 2019 Mar; 110():24-31. PubMed ID: 30739837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
    Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
    Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcome for nasopharyngeal carcinoma in University Malaya Medical Centre from 2004-2008.
    Chee Ee Phua V; Loo WH; Yusof MM; Wan Ishak WZ; Tho LM; Ung NM
    Asian Pac J Cancer Prev; 2013; 14(8):4567-70. PubMed ID: 24083703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
    Song JH; Wu HG; Keam BS; Hah JH; Ahn YC; Oh D; Noh JM; Park HJ; Lee CG; Keum KC; Cha J; Cho KH; Moon SH; Kim JY; Chung WK; Oh YT; Kim WT; Cho MJ; Kay CS; Kim YS
    Cancer Res Treat; 2016 Jul; 48(3):917-27. PubMed ID: 26727716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma : A matched-pair multicenter analysis of outcomes.
    Dong YY; Xiang C; Lu JX; Su YX; Pan YF; Cai R; Zhang RJ; He ZK; Liu ML; Huang H; Bai X; Tang HY; Shi YH; Wang Y; Jiang W
    Strahlenther Onkol; 2016 Jun; 192(6):394-402. PubMed ID: 27215563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
    Chen Y; Sun Y; Liang SB; Zong JF; Li WF; Chen M; Chen L; Mao YP; Tang LL; Guo Y; Lin AH; Liu MZ; Ma J
    Cancer; 2013 Jun; 119(12):2230-8. PubMed ID: 23576020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Descriptive Study of Nasopharyngeal Carcinoma and Treatment Outcomes: An Eight Years Experience in Hadhramout National Cancer Centre, Yemen.
    Bahannan AA; Badheeb AM; Baothman SY
    Gulf J Oncolog; 2019 May; 1(30):61-66. PubMed ID: 31242984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma.
    Goshtasbi K; Lehrich BM; Birkenbeuel JL; Abiri A; Harris JP; Kuan EC
    Otolaryngol Head Neck Surg; 2021 Jul; 165(1):93-103. PubMed ID: 33231508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy concurrently with weekly cisplatin, followed by adjuvant chemotherapy, for N2-3 nasopharyngeal cancer: a multicenter trial of the Forum for Nuclear Cooperation in Asia.
    Ohno T; Thinh DH; Kato S; Devi CR; Tung NT; Thephamongkhol K; Calaguas MJ; Zhou J; Chansilpa Y; Supriana N; Erawati D; Banu PA; Koo CC; Kobayashi K; Nakano T; Tsujii H
    J Radiat Res; 2013 May; 54(3):467-73. PubMed ID: 23192700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and outcome for nasopharyngeal carcinoma.
    Farias TP; Dias FL; Lima RA; Kligerman J; de Sá GM; Barbosa MM; Gonçalves FB
    Arch Otolaryngol Head Neck Surg; 2003 Jul; 129(7):794-9. PubMed ID: 12874084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term outcomes and prognostic factors of n0 stage nasopharyngeal carcinoma: a single institutional experience with 610 patients.
    Sun JD; Chen CZ; Chen JZ; Li DS; Chen ZJ; Zhou MZ; Li DR
    Asian Pac J Cancer Prev; 2012; 13(5):2101-7. PubMed ID: 22901177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma.
    Guo R; Mao YP; Chen L; Tang LL; Zhou GQ; Liu LZ; Tian L; Zeng MS; Jia WH; Shao JY; Lin AH; Ma J
    Oncotarget; 2017 Feb; 8(6):10594-10601. PubMed ID: 27070084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H; Chen L; Zhang Y; Guo R; Li WF; Mao YP; Tan LL; Sun Y; Zhang F; Liu LZ; Tian L; Lin AH; Ma J
    Oncotarget; 2016 Apr; 7(17):24208-16. PubMed ID: 27008701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.
    Buehrlen M; Zwaan CM; Granzen B; Lassay L; Deutz P; Vorwerk P; Staatz G; Gademann G; Christiansen H; Oldenburger F; Tamm M; Mertens R
    Cancer; 2012 Oct; 118(19):4892-900. PubMed ID: 22359313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.